by Andrieux-Meyer I, Tan S-S, Thanprasertsuk S, Salvadori N, Menétrey C, Simon F, Cressey TR, Said HRHM, Hassan MRA, Omar H, Tee H-P, Chan WK, Kumar S, Thongsawat S, Thetket K, Avihingsanon A, Khemnark S, Yerly S, Ngo-Giang-Huong N, Siva S, Swanson A, Goyal V, Bompart F, Pécoul B, Murad S. The Lancet Gastroenterology and Hepatology 2021. doi: 10.1016/S2468-1253(21)00031-5
Summary: In low- and middle-income countries, affordable direct-acting antivirals are urgently needed to treat hepatitis C virus (HCV) infection. The STORM-C-1 trial aimed to assess the efficacy and safety of ravidasvir plus sofosbuvir in adults chronically infected with HCV in Malaysia and Thailand. There was no detectable virus RNA in 97% of the 300 patients included in the first stage of this trial 12 weeks after the end of treatment. The treatment was well-tolerated. Similar results were found in patients with cirrhosis, difficult-to-treat genotype 3 infection, previous interferon treatment, and HIV co-infection. Ravidasvir plus sofosbuvir has the potential to provide an additional affordable, simple, and efficacious public health tool for large-scale implementation to eliminate HCV as a cause of morbidity and mortality.